Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Found vs Invyncible

By GLP-1 ScorecardUpdated

FoundFactor scores not reassessed.
Site position #7

Higher score

InvyncibleFactor scores not reassessed.
Site position #270

Lower score

Score comparison

Found has the higher recorded score — 83.5/100 to 63.6/100.

Found grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Found offers compounded, brand-name and oral GLP-1 routes, but their bills differ: compounded plans include medication and care, while branded medication and labs cost extra.

Before you choose

Before comparing the headline prices, the Found review and the Invyncible review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, Found vs JumpstartMD and Invyncible vs No BS RX compare each of them with another graded program, and the list of alternatives to Found ranks the programs closest to Found on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueFound +33
78
45
Dose & formulationFound +16
94
78
Clinical oversightFound +16
86
70
Labs & monitoringFound +30
82
52
FulfillmentFound +11
84
73
Contract termsInvyncible +7
70
77
Found · top barInvyncible · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricFoundInvyncible
WeighScore83.5/10063.6/100
GradeBC
Site position#7#270
Semaglutide$149 first, then $269 every 28 days on the one-term cash compounded plan (labs extra; confirm selected terms)$145 starter program; supply length and refill cost need confirmation
Tirzepatide$199 first, then $339 every 28 days on the one-term cash compounded plan (labs extra; confirm selected terms)$179 per 4-week starter program (2.5 mg weekly, compounded glycine + B12)
CoverageU.S. service with state, treatment and insurance restrictions; confirm your eligibilityVaries by formulation; glycine/B12 programs exclude AR, CA, IN, MN, OR and SC
Brand-name accessYesYes
Oral / sublingualYesYes
Found

Site position #7 · B

Factor scores not reassessed.

Strengths

  • Current compounded offers include medication, membership and care, with separate semaglutide and tirzepatide price tables
  • Branded injection and oral options are listed, subject to prescription, stock and patient-specific terms
  • Insurance-track clinical visits and cash-pay care are distinguished in the public billing documents
  • Terms name possible independent medical groups and describe check-ins and messaging

What to consider

  • Cash compounded renewal rates differ by molecule and recur every 28 days, not a calendar month
  • Longer-term advertised rates and upfront-payment wording do not settle the selected charge or supply
  • Labs cost extra; insurance-track cost-sharing can add to the bill and does not reimburse compounded-medication fees
  • Refund wording about three days and the first consultation conflicts; rejection of a preferred GLP-1 is not disqualification from all treatment
  • The assigned compounder, actual treating practice and individual license status remain unresolved
  • A brand or oral menu listing does not establish a specific available prescription, complete price or clinical equivalence
Invyncible

Site position #270 · C

Factor scores not reassessed.

Strengths

  • Six pharmacies named with contact details
  • Patients can request a prescription copy or nominate a pharmacy
  • Public catalogs distinguish compounded products, brands and oral options
  • Refills are not automatic; payment is finalized only after physician approval

What to consider

  • Program amounts are not universal monthly prices; dose and formulation can change cost
  • Shipping cost not established on the reviewed program pages
  • State exclusions differ by formulation
  • Compounded medications are not FDA-approved

Featured provider

Found

Factor scores not reassessed.

Found scores 83.5/100 (B). Found offers compounded, brand-name and oral GLP-1 routes, but their bills differ: compounded plans include medication and care, while branded medication and labs cost extra.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard